Medizinische Universität Graz - Research portal
Selected Publication:
Stöger, H; Bauernhofer, T; Schmid, M; Ploner, F; Moser, R; Derstvenscheg, E; Steindorfer, P; Wilders-Truschnig, M; Kuss, I; Samonigg, H.
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Cancer Chemother Pharmacol. 1994; 35(2):174-178
Doi: 10.1007/BF00686643
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Stöger Herbert
- Co-authors Med Uni Graz
- Bauernhofer Thomas
- Ploner Ferdinand
- Samonigg Hellmut
- Schaberl-Moser Renate
- Truschnig-Wilders Martini
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC). In phase I the doses of LV (500 mg/m2, day 1) and FU (350 mg/m2, day 1) were held constant, while the dose of THP (day 1) was escalated, from the initial dose of 10 mg/m2 up to the maximum tolerated dose (MTD). Twenty-eight patients entered phase I, and MTD for THP was defined as 35 mg/m2 in this combination. Dose-limiting toxicities were myelosuppression and hepatotoxicity. In phase II, another 22 patients were treated with THP at a dose level of 30 mg/m2. Including 4 patients already treated at this dose in the first part, 25 patients were evaluable for response: 1 patient obtained a complete response (CR) and 13 showed a partial response (PR), giving an objective response rate of 56%. The median duration of response was 9.1+ months and median survival, 15.5+ months. Side effects were generally mild, with ECOG grade I and II leukopenia in 51% of all cycles and grade III in 3% of the courses. Other toxicity included nausea and vomiting (54% and 8%, respectively) and alopecia (24%), all restricted to ECOG grade I and II. Our results suggest that weekly THP/LV-FU represents an active regimen for first-line treatment of ABC with relative low toxicity.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - drug therapy
- Diarrhea - chemically induced
- Doxorubicin - adverse effects
- Doxorubicin - analogs & derivatives
- Doxorubicin - therapeutic use
- Drug Administration Schedule -
- Female -
- Fluorouracil - adverse effects
- Fluorouracil - therapeutic use
- Humans -
- Leucovorin - adverse effects
- Leucovorin - therapeutic use
- Leukopenia - chemically induced
- Middle Aged -
- Nausea - chemically induced
- Find related publications in this database (Keywords)
- BREAST CANCER
- 4'-O-TETRAHYDROPYRANYL-DOXORUBICIN
- FLUOROURACIL/LEUCOVORIN
- WEEKLY SCHEDULE